14.00
5.41%
-0.80
Grail Inc Aktie (GRAL) Neueste Nachrichten
Grail tests first patient for TROPION-Lung12 Phase 3 study - TipRanks
GRAIL Launches FDA-Approved Phase 3 Trial for Breakthrough Lung Cancer Blood Test | GRAL Stock News - StockTitan
(GRAL) Trading Report - Stock Traders Daily
Wolfe Research Begins Coverage on Grail (NASDAQ:GRAL) - MarketBeat
Wolfe starts Grail at Peer Perform on time and money needs - TipRanks
Golden Grail Beverages Corp. (OTC: GOGY) Retains SmallCapVoice.com Inc. - The Manila Times
Golden Grail Beverages Slashes Share Count 90%, Plans Strategic Acquisitions for 2025 | GOGY Stock News - StockTitan
GRAIL Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
PRIMECAP Management's Strategic Acquisition of GRAIL Inc Shares - GuruFocus.com
Grail Inc. Reports Strong Galleri Test Growth in Q3 2024 - Nasdaq
GRAIL, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
GRAIL Q3 Revenue Surges 38% as Galleri Test Sales Soar, Despite Ongoing Losses | GRAL Stock News - StockTitan
Quantune joins quest for the holy grail of non-invasive glucose monitoring - TechCrunch
How to Take Advantage of moves in (GRAL) - Stock Traders Daily
Grail (GRAL) Scheduled to Post Earnings on Tuesday - MarketBeat
GRAIL to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - PR Newswire
Jim Cramer says Reddit’s surge is about ‘raw user power,’ calls it ‘holy grail’ for advertisers - CNBC
GRAIL to Announce Third Quarter 2024 Financial Results - StockTitan
(GRAL) Trading Advice - Stock Traders Daily
Google: The Bullish Pivot Before The Earnings Grail (NASDAQ:GOOG) - Seeking Alpha
GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation - The Cancer Letter
Nike x Wu-Tang Clan Reunite to Release Legendary Sneaker Grail — NIKE, Inc. - Nike
Illumina Wins Court Fight With EU Over $7 Billion Grail Deal - MSN
Real-world study of Grail’s Galleri consistent with trial data - BioWorld Online
The Jeff Bezos-backed cancer treatment company is being sold for eight billion dollars - Telegrafi
GRAIL Presents Initial Results From REFLECTION Real-World Evidence Study of Galleri® Multi-Cancer Early Detection (MCED) Test at the Early Detection of Cancer Conference - PR Newswire
Health Beat: The 'holy grail' of cancer screening - 69News WFMZ-TV
CEO & Director Of GRAIL Sold 51% Of Their Shares - Simply Wall St
Company commits not to try to crack ‘holy grail’ cement-free formula - Irish Independent
Grail appoints healthcare veteran Sarah Krevans to board By Investing.com - Investing.com Australia
Grail appoints healthcare veteran Sarah Krevans to board - Investing.com
GRAIL Appoints Sarah Krevans to Board of Directors - Quantisnow
Layoff Tracker: Takeda Cuts More Employees, Total Exceeds 1,300 in 2024 - BioSpace
Grail CEO Robert Ragusa sells $1.73 million in stock - Investing.com
How the (GRAL) price action is used to our Advantage - Stock Traders Daily
Health Headlines: Holy Grail of cancer screening - KPLC
GRAIL, Inc. (GRAL): Jeff Bezos Is Buying This Stock Now - Insider Monkey
Grail Inc. executive acquires over $1 million in company stock - Investing.com India
Grail Inc. executive acquires over $1 million in company stock By Investing.com - Investing.com South Africa
Best Life: The ‘Holy Grail’ for cancer screening - Action News 5
Illumina Grail: European Court Limits Commission Jurisdictional Reach in Merger Cases - JD Supra
Illumina falls amid reports of an EU order to sell Grail - MSN
The Taxpayer-Funded GRAIL Galleri-Medicare Study: A Flawed Design - healthaffairs.org
CRCM LP's Strategic Acquisition of GRAIL Inc Shares - GuruFocus.com
Biotech company Grail to lay off 350, more than half in Bay Area - MSN
GRAIL: Post-Spinoff, Illumina Maintains Control And Incentive To Support Success - Seeking Alpha
Closing Strong: GRAIL Inc. (GRAL) Ends at 13.04, Down -6.52 from Last Close - The Dwinnex
Gleeds to relocate to new Fitzrovia HQ - FMJ
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):